Gregory Lucier Acquires 15,000 Shares of DENTSPLY SIRONA (NASDAQ:XRAY) Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory Lucier bought 15,000 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was purchased at an average cost of $12.45 per share, with a total value of $186,750.00. Following the completion of the acquisition, the director directly owned 65,000 shares of the company’s stock, valued at approximately $809,250. The trade was a 30.00% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

DENTSPLY SIRONA Trading Down 0.9%

Shares of NASDAQ XRAY opened at $12.68 on Wednesday. The firm’s 50 day moving average price is $12.69 and its 200-day moving average price is $12.43. DENTSPLY SIRONA Inc. has a 52-week low of $9.85 and a 52-week high of $17.18. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The company has a market cap of $2.53 billion, a PE ratio of -4.23, a P/E/G ratio of 1.50 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. DENTSPLY SIRONA’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the business earned $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts expect that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of XRAY. AQR Capital Management LLC increased its position in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Armistice Capital LLC boosted its holdings in shares of DENTSPLY SIRONA by 1,044.0% in the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after buying an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in DENTSPLY SIRONA by 662.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after buying an additional 4,003,606 shares during the period. Norges Bank bought a new stake in DENTSPLY SIRONA during the second quarter valued at approximately $39,700,000. Finally, Goldman Sachs Group Inc. increased its holdings in DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares during the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on XRAY shares. Wells Fargo & Company increased their price objective on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Barrington Research upped their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and raised their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Finally, Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $14.42.

DENTSPLY SIRONA News Roundup

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: FDA clearance for a dental‑dedicated MRI (ddMRI) with Siemens Healthineers: this first‑of‑its‑kind imaging system expands XRAY’s advanced‑imaging addressable market and could drive higher‑margin equipment sales and recurring service revenue over time. First-ever Dental Dedicated MRI Validated…
• Positive Sentiment: Insider buying from directors (James Forbes and Gregory Lucier): recent purchases (~$12.45–$12.48/share) signal management/board confidence in the stock at current levels and can support sentiment if the buys continue. DENTSPLY SIRONA (NASDAQ:XRAY) Director James Forbes Buys 5,000 Shares
• Neutral Sentiment: Analysts are reworking valuation and risk assumptions: coverage shifts and updated models (discussed in a Yahoo Finance piece) are causing targets and ratings to be revisited — this fuels near‑term volatility but could clarify consensus levels over weeks. How The Dentsply Sirona (XRAY) Story Is Shifting…
• Neutral Sentiment: Presentation transcript from the Leerink Global Healthcare Conference: useful for incremental detail on strategy, margin actions and product cadence — may influence analyst revisions but no single headline takeaway. DENTSPLY SIRONA Presents at Leerink…
• Neutral Sentiment: Short‑interest reports show data anomalies (reported as 0 shares / 0 days to cover) — current disclosures appear unreliable, so there is no clear short‑squeeze or elevated short‑pressure signal from these entries. (Data point: average volume references included in filings.)
• Negative Sentiment: Recent quarterly results/earnings mix: revenue beat but an EPS miss and a negative net margin keep focus on profitability and leverage (market cap and leverage metrics remain notable). Analysts’ target adjustments are mixed (some cuts, some raises), leaving consensus at a “Hold” with average target ~$14.4 — downside remains if execution or margin recovery slows. DENTSPLY SIRONA (XRAY) MarketBeat summary

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.